Unilateral prostate cancer cannot be accurately predicted in low-risk patients.

PURPOSE: Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. We tested the accuracy of unilaterally unremarkable biopsy findings in cases of low-risk PCa patients who are potential candidates for HAT. METHODS AND MATERIALS: The study population consisted of 243 men with clinical stage